Corgenix Secures $1,750,000 Asset Based Credit Facility Representing Initial Gross Proceeds of $1.109 Million
06 Oktober 2009 - 3:15PM
PR Newswire (US)
The financing will enhance the Company's financial position DENVER,
Oct. 6 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC
Bulletin Board: CONX), a worldwide developer and marketer of
diagnostic test kits, has announced that the company has been
successful in securing a $1,750,000 credit facility providing
initial funding of $1,109,000 in an asset based financing from
Summit Financial Resources L.P. This financing allowed for the
retirement of the company's factoring line of credit with
Benefactor Funding Corp., and will be used for working capital
purposes. The agreement with Summit initially has a term of three
years. Under the agreement, the company has the ability to borrow
up to $1.75 million in cash secured by accounts receivable,
inventory and other assets. "This transaction, which is the
culmination of many weeks of discussions with the Summit team, is a
vital element in furthering the execution of our strategic plan,"
stated William Critchfield, Senior Vice President and Chief
Financial Officer of Corgenix. "The new financing allows us to
retire the existing factoring line, provides us with a fresh
infusion of cash, and further provides us much greater financial
flexibility and growth potential going forward." Gordon La Haye,
President & CEO of Summit Financial Resources, commented,
"Summit is very pleased that Corgenix has chosen to replace their
existing line with our working capital facility. We look forward to
helping them achieve their growth objectives with this new, more
flexible credit line." The Summit Financial Resources team was led
by Renee Jackson, VP, Business Development Officer for the
Intermountain Region, based in Denver. "We have been extremely
impressed by the professionalism and the very organized approach
put forth by Summit," stated Critchfield. "Summit's asset size
along with the broad expertise possessed by their management and
lending team is very impressive. The fact that they were equally
excited to have Corgenix as a portfolio company, after their having
performed extremely comprehensive due diligence on our company,
bodes very well for the future of our Company." About Corgenix
Medical Corporation Corgenix is a leader in the development and
manufacturing of specialized diagnostic kits for immunology
disorders, vascular diseases and bone and joint disorders,
including the world's only non-blood-based test for aspirin effect.
Corgenix diagnostic products are commercialized for use in clinical
laboratories throughout the world. The company currently sells over
50 diagnostic products through a global distribution network and
has significant experience advancing products through the FDA
process. More information is available at http://www.corgenix.com/.
About Summit Financial Resources L.P. Summit Financial Resources is
a nationally recognized provider of working capital financing to
small and medium-sized businesses in a broad range of industries.
With 16 offices nationwide and over 20 years of experience, Summit
has established itself as one of the largest and fastest growing
companies in its industry. Statements in this press release that
are not strictly historical facts are "forward-looking" statements
(identified by the words "believe", "estimate", "project", "expect"
or similar expressions) within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements
inherently involve risks and uncertainties that could cause actual
results to differ materially from the forward-looking statements.
Factors that would cause or contribute to such differences include,
but are not limited to, continued acceptance of the Company's
products and services in the marketplace, competitive factors,
changes in the regulatory environment, and other risks detailed in
the Company's periodic report filings with the Securities and
Exchange Commission. The statements in this press release are made
as of today, based upon information currently known to management,
and the Company does not undertake any obligation to publicly
update or revise any forward-looking statements. DATASOURCE:
Corgenix Medical Corporation CONTACT: Company, William Critchfield,
Senior VP and CFO of Corgenix Medical Corp., +1-303-453-8903, ; or
Media, Dan Snyders, Vice President and Public Relations Supervisor
of Armada Medical Marketing, +1-303-623-1190, ext. 230, Fax,
+1-303-623-1191, Web Site: http://www.corgenix.com/
Copyright